GRFS Stock Overview
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.39 |
52 Week High | €12.15 |
52 Week Low | €5.30 |
Beta | 0.68 |
1 Month Change | 0.47% |
3 Month Change | -16.25% |
1 Year Change | -11.25% |
3 Year Change | -64.30% |
5 Year Change | -66.26% |
Change since IPO | -3.52% |
Recent News & Updates
Grifols: Q4 Was Positive, Still Too Many Question Marks
Mar 05Grifols: I've Read The Short-Seller Report, And I Mostly Disagree
Jan 10Recent updates
Grifols: Q4 Was Positive, Still Too Many Question Marks
Mar 05Grifols: I've Read The Short-Seller Report, And I Mostly Disagree
Jan 10Grifols inks 15-year deal with Canada for plasma-derived therapies
Sep 07Grifols: Every Cloud Has A Silver Lining
Jul 29Grifols: Long Only
May 10Grifols shares rise after Andorra Development and Investment deal
Apr 28Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing
Jan 03Grifols Class B: Buy The Recovery In The U.S. Plasma Business
Nov 11Grifols S.A. goes ex-dividend tomorrow
Oct 29Shareholder Returns
GRFS | US Biotechs | US Market | |
---|---|---|---|
7D | -2.9% | 1.5% | 1.2% |
1Y | -11.3% | 1.1% | 24.7% |
Return vs Industry: GRFS underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: GRFS underperformed the US Market which returned 24.7% over the past year.
Price Volatility
GRFS volatility | |
---|---|
GRFS Average Weekly Movement | 12.1% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRFS's share price has been volatile over the past 3 months.
Volatility Over Time: GRFS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1909 | 23,744 | Nacho Abia | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
GRFS fundamental statistics | |
---|---|
Market cap | US$5.41b |
Earnings (TTM) | US$63.48m |
Revenue (TTM) | US$7.05b |
95.9x
P/E Ratio0.9x
P/S RatioIs GRFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRFS income statement (TTM) | |
---|---|
Revenue | €6.59b |
Cost of Revenue | €4.10b |
Gross Profit | €2.49b |
Other Expenses | €2.44b |
Earnings | €59.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | 0.087 |
Gross Margin | 37.84% |
Net Profit Margin | 0.90% |
Debt/Equity Ratio | 119.6% |
How did GRFS perform over the long term?
See historical performance and comparison